Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesCardiologyCurative Cardiology Coverage Update | OpenPayer
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentCurativePolicy CHP-OP-2026-006

    Diagnostic Cardiology Tests & Procedures

    Customize your policy alerts

    Sign up for curative Policy CHP-OP-2026-006 alerts

    Get alerted when Policy CHP-OP-2026-006 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical-necessity criteria for outpatient diagnostic and selected interventional cardiology services, including echocardiography, stress testing, rhythm monitoring, cardiac imaging, catheterization, electrophysiology procedures, cardioversion, pericardiocentesis, and selected structural interventions.

    Policy Summary
    PayerCurative
    PolicyDiagnostic Cardiology Tests & Procedures
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNovember 5, 2026
    Next Review DateN/A
    Key ActionDocument the indication, symptom frequency, prior ECG and monitoring results, selected monitoring duration, and how the result will change treatment.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12Medical-necessity criteria sections
    All agesApplicable population
    6–12 monthsAortic repeat-imaging interval
    30 daysRemote review period
    13Documentation elements

    Medical Necessity Criteria

    A. Transthoracic echocardiography

    TTE is medically necessary when ANY of the following is met.

    TTE indications: Initial evaluation of suspected structural, valvular, myocardial, or pericardial disease; reassessment after a clinical-status change or intervening event when results may change management; guideline-interval surveillance of a known condition; evaluation of a cardioembolic source after ischemic stroke or TIA; suspected pulmonary hypertension, pericardial effusion, or endocarditis; or evaluation of known cardiomyopathy or heart failure when results guide treatment, device candidacy, or advanced-therapy evaluation.

    Surveillance includes native valve disease, prosthetic valves, thoracic aortic dilation, congenital heart disease, cardiomyopathy, and heart failure.

    Cardio-oncology surveillance: Baseline TTE before cardiotoxic therapy when cardiotoxicity risk is moderate or higher, or before any HER2-targeted therapy; interval TTE during HER2-targeted or anthracycline therapy; repeat TTE after a qualifying LVEF or strain decline; or survivorship evaluation 6 to 12 months after high-risk therapy.LVEF decline >=10 percentage points to below 50%, or relative GLS decline >15% from baseline

    Testing should guide therapy interruption, cardioprotection, or survivorship management.

    B. Transesophageal echocardiography and agitated-saline studies

    TEE is medically necessary when ANY of the following is met.

    TEE and agitated-saline indications: Suspected endocarditis with nondiagnostic or negative TTE and persistent suspicion, prosthetic-valve endocarditis, or suspected perivalvular complication; exclusion of left atrial or appendage thrombus before cardioversion without at least 3 weeks of therapeutic anticoagulation or before ablation or appendage occlusion; inadequate TTE for a management-changing valvular, prosthetic, aortic, or congenital question; or PFO/atrial-septal evaluation after embolic-appearing stroke with no other mechanism when the member may be a closure candidate.Generally age 60 or younger for PFO closure evaluation

    For PFO evaluation, document prior agitated-saline TTE or stroke workup and that the result will guide closure.

    C. Stress testing

    Stress testing is medically necessary when ALL of the following are met.

    Stress-test requirements

    • Qualifying indication: Stable chest pain or anginal equivalent with intermediate or high CAD pretest probability, or known CAD with new or worsening symptoms; intermediate-risk acute chest pain after ACS is excluded; post-ACS risk stratification; elevated-risk noncardiac surgery with poor or unknown functional capacity when results change management; equivocal, nondiagnostic, or discordant prior testing; or another documented stress-dependent physiologic question that changes management.Poor or unknown functional capacity: fewer than 4 METs
    • Appropriate modality: Exercise ECG when the member can exercise and has an interpretable baseline ECG; stress imaging when the ECG is uninterpretable, exercise is inadequate, or ischemia location and extent are needed.

      Examples of an uninterpretable ECG include LBBB, paced rhythm, pre-excitation, or at least 1 mm resting ST depression.

    • Safety requirement:

    D. External ambulatory rhythm monitoring

    External ambulatory ECG monitoring is medically necessary when ALL of the following are met.

    External ambulatory monitoring requirements

    • Qualifying indication: Arrhythmic syncope or presyncope after history, examination, and 12-lead ECG; palpitations or concerning dizziness, lightheadedness, or symptomatic bradycardia requiring symptom-rhythm correlation; AF detection after cryptogenic ischemic stroke or TIA; or initiation, adjustment, or discontinuation of antiarrhythmic or rate-control therapy or assessment of AF burden after ablation.
    • Appropriate duration and documentation: Monitoring duration matches symptom frequency, and the record states symptom frequency, prior ECG and monitoring results, and how the result will change treatment.24-48 hour Holter for daily symptoms; up to 14 days, 30-day event, or telemetry monitoring for less frequent symptoms

      Mobile cardiac telemetry is used when real-time detection of a potentially dangerous arrhythmia matters.

    E. Implanted monitor evaluation

    Implanted device evaluation is medically necessary when the requirements of the applicable subsection are met.

    Remote rhythm evaluation, 93298: The device is implanted and active for a supported indication and managed by the billing professional; the period includes at least one received transmission or stored episode requiring professional analysis; and the record contains analysis, interpretation, and a signed report without duplicate review of the same data.

    Supported indications include unexplained syncope, palpitations, cryptogenic stroke, or AF management.

    Remote physiologic monitoring evaluation, 93297: An active implanted cardiovascular physiologic monitor is present for heart failure or another condition in which data guide management; physiologic data were received and reviewed with a signed report documenting findings and resulting action; and reporting is separate from rhythm interrogation only as coding rules allow.
    In-person device evaluation: In-person programming, interrogation, or peri-procedural evaluation is performed at consensus-consistent device-check intervals or for symptoms, alerts, or a procedure requiring reprogramming.

    F. Noncoronary CT angiography of the chest

    Chest CTA for a cardiovascular indication is medically necessary when ANY of the following is met.

    Noncoronary chest CTA indications: Characterization of thoracic aortic dilation or aneurysm; surveillance of known thoracic aortic aneurysm or dilation; suspected acute aortic syndrome; or pulmonary-vein and left-atrial anatomic mapping before qualifying AF ablation or appendage occlusion, or evaluation of suspected pulmonary-vein stenosis after ablation.Repeat imaging generally 6-12 months after initial detection, then according to diameter, growth rate, and cause

    Shorter intervals apply to larger aneurysms, rapid growth, or heritable thoracic aortic disease; imaging is also supported before planned intervention or after repair at guideline intervals.

    G. Cardiopulmonary exercise testing

    CPET is medically necessary when ANY of the following is met and the result will guide diagnosis, prognosis, or therapy.

    CPET indications: Heart failure with reduced or preserved EF when peak oxygen uptake guides transplant, durable mechanical support, advanced-therapy candidacy, or prognosis; unexplained exertional dyspnea or exercise intolerance after initial cardiac and pulmonary evaluation; or hypertrophic cardiomyopathy or congenital heart disease when functional capacity guides intervention timing or advanced therapy.

    H. Cardiac catheterization, coronary angiography, and intracoronary physiology and imaging

    Diagnostic catheterization is medically necessary when ANY of the following is met.

    Catheterization and PCI indications: High-risk noninvasive findings in a revascularization candidate; acute coronary syndrome or other unstable presentation; persistent limiting angina despite guideline-directed therapy; evaluation of valvular, congenital, cardiomyopathic, pericardial, or pulmonary hypertensive disease when noninvasive data are insufficient or hemodynamics are needed; intracoronary physiology or intravascular imaging for an intermediate lesion, left main or complex PCI, or stent optimization; or PCI for ACS or stable disease with significant stenosis and limiting symptoms despite medical therapy or high-risk anatomy.Significant stenosis may be physiologically significant or high-grade

    Congenital catheterization is included.

    I. Electrophysiology study and catheter ablation

    EP study or catheter ablation is medically necessary when ANY of the following is met.

    EP study and ablation indications: Diagnostic EP study for unexplained syncope with structural or conduction disease, uncertain wide-complex tachycardia, or risk stratification guiding device or ablation therapy; AF ablation for selected symptomatic paroxysmal AF as first-line rhythm control, symptomatic paroxysmal or persistent AF when drugs are ineffective, not tolerated, or not preferred, or selected AF with HFrEF; or ablation of symptomatic, recurrent, drug-refractory, or high-risk SVT, atrial flutter, accessory pathway, or ventricular arrhythmia when guideline-recommended.

    J. Elective external cardioversion

    Elective external electrical cardioversion is medically necessary when ALL of the following are met.

    Elective cardioversion requirements

    • Rhythm-control indication: Persistent AF or atrial flutter is present in a member for whom rhythm control has been selected or sinus-rhythm restoration is needed to assess symptoms or ventricular function.
    • Thromboembolic protection follows the guideline.At least 3 weeks therapeutic anticoagulation before, or TEE excluding thrombus; AF duration under 48 hours may qualify in a low-risk member; at least 4 weeks anticoagulation after

    K. Pericardiocentesis

    Pericardiocentesis is medically necessary when ANY of the following is met.

    Pericardiocentesis indications: Cardiac tamponade or large effusion with hemodynamic compromise; suspected bacterial, tuberculous, or neoplastic effusion when fluid analysis will establish the diagnosis; or symptomatic moderate-to-large effusion unresponsive to medical therapy.

    L. Structural interventions

    The transcatheter interventions are medically necessary when ANY of the following is met.

    Interatrial closure and alcohol septal ablation indications: Secundum ASD with right-heart enlargement or Qp:Qs at least 1.5 without prohibitive pulmonary vascular resistance; PFO in a generally age-60-or-younger member with embolic-appearing ischemic stroke, no other identified mechanism after thorough evaluation, and documented shared decision-making; or obstructive HCM suitable for alcohol septal ablation with qualifying LVOT gradient and symptoms despite guideline-directed therapy.LVOT gradient >=50 mmHg at rest or with provocation; NYHA III-IV, or NYHA II with exertional syncope

    Alcohol septal ablation requires suitable anatomy and treatment at an experienced center.

    Pericardiocentesis

    Medically necessary when ANY of the following are met.

    Pericardiocentesis indications: Pericardiocentesis is medically necessary for cardiac tamponade or a large effusion with hemodynamic compromise; suspected bacterial, tuberculous, or neoplastic pericardial effusion when fluid analysis will establish the diagnosis; or a symptomatic moderate-to-large effusion that does not respond to medical therapy.

    Structural interventions

    These transcatheter interventions are medically necessary when ANY of the following are met.

    Structural intervention indications: Transcatheter closure of a secundum atrial septal defect with right-heart enlargement, or Qp:Qs of 1.5 or more, without pulmonary vascular resistance that rules out closure; transcatheter PFO closure generally in a member age 60 or younger with an embolic-appearing ischemic stroke, no other identified mechanism after thorough evaluation, and documented shared decision-making; or alcohol septal ablation for obstructive hypertrophic cardiomyopathy with LV outflow tract gradient of at least 50 mmHg at rest or with provocation, NYHA class III or IV symptoms, or class II symptoms with exertional syncope, despite guideline-directed medical therapy, when anatomically suitable and performed at an experienced center.ASD Qp:Qs >=1.5; HCM LVOT gradient >=50 mmHg; PFO age generally <=60 years

    Implantable pulmonary artery pressure sensor

    Medically necessary when ALL of the following are met.

    • Clinical eligibility: The member has heart failure with NYHA class II or III symptoms and either a heart failure hospitalization in the previous 12 months or elevated natriuretic peptides.NYHA class II or III; hospitalization within previous 12 months OR elevated natriuretic peptides
    • Ongoing management: The member is receiving guideline-directed medical therapy and is followed by a heart failure program that will review pressure data and adjust therapy.

    Fetal echocardiography

    Medically necessary when ANY of the following indications is met; timing requirements also apply.

    Fetal echocardiography indications: An abnormal or incomplete cardiac view on screening obstetric ultrasound; maternal pregestational diabetes, phenylketonuria, SSA/SSB antibodies, rubella infection, first-degree relative with congenital heart disease, or retinoid exposure; fetal hydrops, extracardiac anomaly, chromosomal abnormality, monochorionic twinning, or nuchal translucency of 3.5 mm or more; or, on physician review when the guideline says the study may be considered, in vitro fertilization, nuchal translucency of 3.0 to 3.4 mm, or first-trimester ACE-inhibitor or paroxetine exposure.Nuchal translucency >=3.5 mm is an indication; 3.0-3.4 mm may be considered
    Timing requirements: A comprehensive study is performed at 18-22 weeks. An early study at 12-14 weeks for a high-risk pregnancy is followed by a repeat second-trimester study.

    Repeat diagnostic testing

    Repeat diagnostic testing is medically necessary when ANY of the following are met.

    Repeat-service criteria: There has been a change in symptoms, examination, or clinical status since the prior study; the guideline-defined surveillance interval for the condition and severity has been reached; the prior study was technically inadequate or nondiagnostic; or a planned procedure or therapy change requires updated data, such as cardio-oncology monitoring or pre-procedural planning.

    Frequency and site-of-care limitations

    The following limitations apply.

    Monitoring frequency and site-of-care limitations: Only one external ambulatory monitoring episode per symptom evaluation is supported unless the first was nondiagnostic and symptoms persist or treatment response must be assessed. Remote rhythm review 93298 and remote physiologic review 93297 are each reported no more than once per 30-day period per device, as coding rules allow. Outpatient cardiac rehabilitation is reviewed under Policy 103, and implantation of an implantable loop recorder or subcutaneous cardiac rhythm monitor is reviewed under Policy 16 while this policy governs evaluation of the implanted device.One external monitoring episode per symptom evaluation; 93298 and 93297 no more than once per 30 days per device

    Determination authority and partial approval

    Coverage determination and review authority.

    Adverse determination requirements: An adverse determination requires review by a licensed physician of the same or similar specialty, after offering the requesting provider a peer-to-peer discussion. The reviewing physician must also meet the plan's applicable licensure, specialty, and medical-director requirements for the situs state.

    Automated systems and non-physician clinical reviewers may approve a request in full or in part but may not issue an adverse determination.

    Excess quantity, units, or duration: If the service meets criteria but the requested quantity, units, or duration exceed what the documentation supports, approve the supported portion and review only the unsupported increment.

    The absence of a criterion addressing a service is not itself a basis for an adverse determination; a physician reviews the request using generally accepted standards of medical practice.

    Ambulatory ECG monitoring is not supported as a screening test. It is intended to detect and document symptomatic transient arrhythmias or to guide antiarrhythmic therapy, with monitoring selected according to the member’s symptoms and clinical indication.

    Routine periodic stress testing is not supported for stable, asymptomatic patients. Testing should be tied to symptoms, clinical risk, or another indication in which the result is expected to change management.

    Stress testing, echocardiography, or ambulatory monitoring is not medically necessary as screening for an asymptomatic, low-risk member without a risk-based indication, because the testing is not expected to change management.

    Routine periodic stress testing is not medically necessary for stable chronic coronary disease without a change in symptoms, including routine testing after revascularization. Surveillance testing should be prompted by a clinical change or another indication that may alter management.

    Repeat echocardiography of stable disease sooner than the guideline-defined surveillance interval is not medically necessary when there has been no change in clinical status, because the study duplicates the prior evaluation.

    Echocardiography is not medically necessary for an isolated soft midsystolic murmur in an asymptomatic member with an otherwise normal examination; the murmur is likely innocent.

    Preoperative stress testing or echocardiography is not medically necessary before low-risk surgery, or when functional capacity is 4 metabolic equivalents or more and there are no new symptoms, when the result would not change perioperative management.

    Invasive coronary angiography is not medically necessary for a low-risk, stable member with reassuring noninvasive testing.

    CPT 93298 does not meet criteria without an active implanted rhythm monitor, a qualifying transmission and signed professional report, or a documented professional review. Connectivity-only surveillance and duplicate review of the same data and period are not supported.

    Fetal echocardiography is not medically necessary for gestational diabetes diagnosed after the second trimester, maternal obesity alone, SSRI exposure other than paroxetine, warfarin exposure, or an isolated single umbilical artery when the anatomy-scan cardiac screening is adequate. These scenarios are not considered indicated under the applicable guidance.

    Covered Services and Coding

    Implanted monitor evaluationCPTCovered
    93298Remote rhythm evaluation of a subcutaneous cardiac rhythm monitor or implantable loop recorder
    93297Remote physiologic monitoring evaluation
    Noncoronary chest CT angiographyCPTCovered
    71275Noncoronary CT angiography of the chest for thoracic aorta and pulmonary veins
    Cardiopulmonary exercise testingCPTCovered
    94621Cardiopulmonary exercise testing
    Percutaneous coronary interventionCPTCovered
    92920Percutaneous coronary intervention
    Elective external cardioversionCPTCovered
    92960Elective external electrical cardioversion
    PericardiocentesisCPTCovered
    33016Pericardiocentesis
    33017Pericardiocentesis
    Structural interventionsCPTCovered
    93580Transcatheter interatrial closure
    93583Alcohol septal ablation
    Echocardiography (TTE, TEE, stress, Doppler)CPT
    93303Echocardiography (TTE, TEE, stress, Doppler)
    93307Echocardiography (TTE, TEE, stress, Doppler)
    93308Echocardiography (TTE, TEE, stress, Doppler)
    93313Echocardiography (TTE, TEE, stress, Doppler)
    93315Echocardiography (TTE, TEE, stress, Doppler)
    93317Echocardiography (TTE, TEE, stress, Doppler)
    93325Echocardiography (TTE, TEE, stress, Doppler)
    93351Echocardiography (TTE, TEE, stress, Doppler)
    93355Echocardiography (TTE, TEE, stress, Doppler)
    93356Echocardiography (TTE, TEE, stress, Doppler)
    External ambulatory monitoringCPT
    93228External ambulatory monitoring
    93229External ambulatory monitoring
    93241External ambulatory monitoring
    93271External ambulatory monitoring
    Implanted device and monitor evaluationCPT
    93281Implanted device and monitor evaluation
    93282Implanted device and monitor evaluation
    93286Implanted device and monitor evaluation
    93287Implanted device and monitor evaluation
    93291Implanted device and monitor evaluation
    93297Implanted device and monitor evaluation
    93298Implanted device and monitor evaluation
    Cardiac PET/CT perfusionCPT
    78430Cardiac PET/CT perfusion
    78431Cardiac PET/CT perfusion
    78432Cardiac PET/CT perfusion
    78433Cardiac PET/CT perfusion
    Chest CTA and angiographyCPT
    71275Chest CTA and angiography
    75774Chest CTA and angiography
    Catheterization, intracoronary physiology and imaging, PCICPT
    92920Catheterization, intracoronary physiology and imaging, PCI
    92978Catheterization, intracoronary physiology and imaging, PCI
    93451Catheterization, intracoronary physiology and imaging, PCI
    93454Catheterization, intracoronary physiology and imaging, PCI
    93458Catheterization, intracoronary physiology and imaging, PCI
    93460Catheterization, intracoronary physiology and imaging, PCI
    93462Catheterization, intracoronary physiology and imaging, PCI
    93572Catheterization, intracoronary physiology and imaging, PCI
    93593Catheterization, intracoronary physiology and imaging, PCI
    93594Catheterization, intracoronary physiology and imaging, PCI
    1–10 of 15
    1/2
    Electrophysiology study and ablationCPT
    93609Electrophysiology study and ablation
    93620Electrophysiology study and ablation
    93653Electrophysiology study and ablation
    93655Electrophysiology study and ablation
    93656Electrophysiology study and ablation
    93657Electrophysiology study and ablation
    93662Electrophysiology study and ablation
    Cardioversion, pericardiocentesis, structural interventionsCPT
    92960Cardioversion, pericardiocentesis, structural interventions
    33016Cardioversion, pericardiocentesis, structural interventions
    33017Cardioversion, pericardiocentesis, structural interventions
    93580Cardioversion, pericardiocentesis, structural interventions
    93583Cardioversion, pericardiocentesis, structural interventions
    Physiologic sensors, CPET, and othermixed
    C2624Physiologic sensors, CPET, and other
    94621Physiologic sensors, CPET, and other
    93702Physiologic sensors, CPET, and other
    93799Physiologic sensors, CPET, and other
    LVEF decline during cardiotoxic therapy
    ThresholdLVEF decline of 10 percentage points or more to below 50%
    Clinical settingDuring cardiotoxic cancer therapy
    PurposeRepeat TTE to guide therapy interruption or cardioprotection
    Global longitudinal strain decline

    Documentation and Review Requirements

    Prior Authorization

    Physician Review Required for Adverse Determinations

    An adverse determination may not be issued by an automated system or non-physician reviewer. It must be made by a licensed physician of the same or similar specialty, after offering the requesting provider a peer-to-peer discussion and meeting applicable state licensure and medical-director requirements.

    Billing Rule

    Partial Approval for Supported Quantities or Duration

    When the documentation supports only part of the requested service, approve the supported quantity, units, or duration and refer only the unsupported increment for review.

    • The supported portion is approved; only the excess quantity, units, or duration is subject to physician review.

    Policy Rationale

    Cardiac diagnostic testing should reflect symptoms, pretest probability, and whether the result will change management. Low-risk acute chest pain, defined as an estimated 30-day risk of death or major adverse cardiac events below 1%, may not require further testing; intermediate-risk patients may undergo anatomic or functional testing, while high-risk findings may require urgent invasive evaluation. Echocardiographic surveillance follows disease-specific intervals, and ambulatory rhythm monitoring should match symptom frequency.

    Key Terms and Thresholds

    Pretest probability
    DefinitionEstimated probability of obstructive coronary artery disease based on age, sex, and symptom character
    Guideline basisDescribed in the 2021 chest pain guideline
    Low probabilityGenerally 15 percent or less
    Guideline-defined surveillance interval
    DefinitionRepeat-imaging interval stated in the applicable ACC/AHA or specialty-society guideline
    SpecificityApplies to a specific condition and severity
    Examples
    Policy Summary
    PayerCurative
    PolicyDiagnostic Cardiology Tests & Procedures
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNovember 5, 2026
    Next Review DateN/A
    Key ActionDocument the indication, symptom frequency, prior ECG and monitoring results, selected monitoring duration, and how the result will change treatment.
    SourceLink
    On This Page
    Medical Necessity CriteriaCovered Services and CodingDocumentation and Review RequirementsPolicy RationaleKey Terms and Thresholds
    No high-risk finding requiring urgent invasive evaluation is present.
    ThresholdRelative global longitudinal strain decline of more than 15% from baseline
    Clinical settingCardio-oncology surveillance
    PurposeRepeat TTE to guide therapy interruption or cardioprotection
    Rapid thoracic aortic growth
    Two-year growth rate0.3 cm or more per year over 2 years
    One-year growth rate0.5 cm or more in 1 year
    ResponseShorter imaging intervals apply for rapid growth
    Secundum ASD shunt ratio
    Qp:Qs threshold1.5 or more
    Qualifying conditionSecundum atrial septal defect with right-heart enlargement or qualifying shunt
    Additional requirementPulmonary vascular resistance must not rule out closure
    Alcohol septal ablation LV outflow tract gradient
    Resting gradientAt least 50 mmHg
    Provoked gradientAt least 50 mmHg with provocation also qualifies
    ProcedureAlcohol septal ablation for obstructive hypertrophic cardiomyopathy
    Alcohol septal ablation symptoms
    NYHA class III or IVQualifying symptoms despite guideline-directed medical therapy
    NYHA class IIQualifies when accompanied by exertional syncope
    Additional requirementSuitable anatomy and treatment at an experienced center are required
    ASD shunt ratio
    Qp:Qs threshold1.5 or more
    ProcedureTranscatheter closure of a secundum atrial septal defect
    Additional requirementPulmonary vascular resistance must not rule out closure
    Alcohol septal ablation LV outflow tract gradient
    Resting gradientAt least 50 mmHg
    Provoked gradientAt least 50 mmHg with provocation also qualifies
    Clinical conditionObstructive hypertrophic cardiomyopathy suitable for alcohol septal ablation
    Alcohol septal ablation symptoms
    NYHA class III or IVQualifying symptoms despite guideline-directed medical therapy
    NYHA class IIQualifies with exertional syncope despite guideline-directed medical therapy
    Treatment settingSuitable anatomy and an experienced center are required
    PFO closure age
    AgeGenerally age 60 or younger
    Stroke historyEmbolic-appearing ischemic stroke is required
    Other evaluationNo other identified mechanism after thorough evaluation, with shared decision-making documented
    Fetal echocardiography nuchal translucency
    Definite indicationNuchal translucency of 3.5 mm or more
    Physician-review rangeNuchal translucency of 3.0 to 3.4 mm may be considered
    ContextNuchal translucency is a fetal indication for fetal echocardiography
    Fetal echocardiography timing
    Comprehensive study18 to 22 weeks
    Early high-risk study12 to 14 weeks
    Follow-upAn early high-risk study is followed by a repeat second-trimester study
    Thoracic aortic diameter red flag
    Red-flag diameterThoracic aortic diameter of 5.0 to 5.5 cm or more
    Required responseExpedite imaging and surgical referral
    SurveillanceShorter surveillance intervals are supported
    Aortic growth red flag
    Red-flag growthAortic growth of 0.5 cm or more in 1 year
    Required responseExpedite imaging and surgical referral
    SurveillanceShorter surveillance intervals are supported
    LVEF cardiotoxicity red flag
    LVEF thresholdDrop in LVEF below 40 percent
    Clinical settingDuring cardiotoxic cancer therapy
    Required responseExpedite cardio-oncology evaluation and repeat imaging; do not delay for interval limits
    Remote review frequency
    93298 frequencyNo more than once per 30-day period per device
    93297 frequencyNo more than once per 30-day period per device
    Coding conditionFrequency limit applies as coding rules allow
    Documentation Required

    External Rhythm-Monitoring Records

    For external ambulatory ECG monitoring, document the indication, symptom pattern, relevant prior testing, selected device, monitoring duration, and how the result will affect treatment.

    • Include suspected arrhythmic syncope or presyncope, palpitations or concerning dizziness, cryptogenic stroke/TIA evaluation, or therapy/burden assessment when applicable.
    • Document symptom frequency, prior ECG and monitoring results, and why the device and duration fit the symptom frequency.
    Documentation Required

    Loop-Recorder Remote Evaluation Records

    Remote rhythm evaluation of an implantable loop recorder or subcutaneous cardiac rhythm monitor requires an active implanted device for a supported indication and a professional review of data actually received during the billing period.

    • Document the indication, active device status, transmission or stored episode requiring analysis, clinically relevant findings, and a signed interpretation.
    • Enrollment or connectivity alone is insufficient, and the service must not duplicate another professional review of the same data and period.
    Documentation Required

    Physiologic-Monitor Evaluation Records

    Remote physiologic-monitor evaluation requires an active implanted cardiovascular physiologic monitor and received physiologic data that were reviewed during the period.

    • Document the device, indication, received data, findings, signed report, and resulting management action such as medication adjustment or patient outreach.
    • Report separately from rhythm interrogation of the same device only when coding rules permit.
    Documentation Required

    PFO or Atrial-Septal TEE Records

    For TEE evaluating PFO or atrial-septal anatomy, document an embolic-appearing ischemic stroke with no other identified mechanism, candidacy for closure, and the prior evaluation supporting the request.

    • Include a prior agitated-saline TTE or the relevant stroke-workup documentation.
    • State how the TEE result will guide the closure decision.
    Documentation Required

    Stress-Test Records

    Stress-test requests must document the clinical indication, risk or pretest assessment, functional capacity, baseline ECG interpretation, selected modality, and why that modality is appropriate.

    • Use exercise ECG when the member can exercise and has an interpretable baseline ECG.
    • Use stress imaging when the ECG is uninterpretable, exercise capacity is inadequate, or ischemia location and extent are needed.
    • Confirm that no high-risk finding requires urgent invasive evaluation.
    Documentation Required

    Elective Cardioversion Records

    Elective external cardioversion requires persistent atrial fibrillation or flutter with a rhythm-control rationale, or a need to assess symptoms or ventricular function after restoring sinus rhythm.

    • Document the rhythm-control rationale and prior therapies.
    • Document thromboembolic protection: at least 3 weeks of therapeutic anticoagulation, or TEE excluding thrombus when appropriate, with at least 4 weeks of anticoagulation after cardioversion.
    Documentation Required

    Clinical Purpose and Risk

    Document the clinical purpose of each requested test or procedure and the applicable risk context. The purpose may be diagnostic evaluation, treatment planning, disease surveillance, or physiologic monitoring; new symptoms are not required when a documented surveillance indication applies.

    • Include symptoms, pertinent examination findings, and estimated pretest probability or risk category when relevant.
    Documentation Required

    Remote Device Review Documentation

    For remote device review, document the device type, implant indication, active status, transmission dates, findings, signed professional report, and resulting management.

    • For CPT 93298 and 93297, show that data were actually received and reviewed during the applicable period.
    • Document any management action or clinical follow-up resulting from the review.
    Documentation Required

    Cardio-Oncology Documentation

    Cardio-oncology records must identify the cardiotoxic agent and treatment exposure and establish the baseline and follow-up cardiac assessment plan.

    • Include cumulative dose or exposure, baseline LVEF and strain, risk category, and prior findings.
    • State the planned response if cardiac function changes.
    Documentation Required

    Interventional Procedure Documentation

    For ablation, cardioversion, and structural procedures, document the rhythm, prior therapies, anticoagulation status, hemodynamic data, and procedural rationale.

    • Include relevant gradients and other hemodynamic findings.
    • Explain how the procedure is expected to affect management.
    Documentation Required

    Fetal Echocardiography Documentation

    Fetal echocardiography requests must document the gestational age and the specific maternal or fetal indication supporting the study.

    • The indication should be clinically relevant to fetal cardiac assessment rather than an unsupported screening scenario.
    Documentation Required

    Document Management Impact

    State how the requested test or procedure will change diagnosis, treatment, surveillance, or follow-up management.

    • Include the anticipated decision or action that depends on the result.
    Documentation Required

    Congenital Heart Disease Surveillance

    Congenital heart disease surveillance documentation must identify the lesion and the clinical reason for the proposed interval.

    • Include any residual shunt or hemodynamic concern, the prior study and date, and the proposed surveillance interval.
    Documentation Required

    CPET Documentation

    For CPET, document prior cardiac and pulmonary testing, the functional limitation being evaluated, and the treatment or advanced-therapy decision that the measured exercise response will inform.

    • Identify whether the result will guide treatment, rehabilitation, or an advanced-therapy decision.
    Documentation Required

    Support Requested Quantity and Duration

    Requested quantities, units, and durations must be supported by the clinical indication and documentation. If only part of the request is supported, the supported portion may be approved and the excess referred for review.

    • Explain why the requested amount and duration are necessary for the member's symptoms, surveillance interval, or management plan.
    Denial Risk

    Remote Rhythm Review Requires Received Data and Signed Interpretation

    CPT 93298 is not supported by enrollment or connectivity alone. A qualifying received transmission or stored episode requiring professional analysis, clinically relevant interpretation, and a signed report are required.

    • The device must be implanted and active for a supported indication.
    • Do not approve connectivity-only surveillance or a review without received data and signed interpretation.
    Denial Risk

    Complete Remote Physiologic Monitoring Requirements

    Remote physiologic monitoring requires an active implanted cardiovascular physiologic monitor, received and reviewed physiologic data, and a signed interpretation documenting findings and resulting action.

    • Enrollment or device connectivity without received data is insufficient.
    • Document the device, indication, review period, findings, signed report, and management response.

    Unsupported block type: denial_risk擬

    Unsupported block type: denial_risk‮

    Unsupported block type: denial_risk擬

    Unsupported block type: denial_risk擬

    Unsupported block type: denial_risk擬

    Unsupported block type: denial_risk擬

    Unsupported block type: denial_risk擬

    Denial Risk

    Non-Indicated Fetal Echocardiography

    Fetal echocardiography is not indicated for gestational diabetes diagnosed after the second trimester, maternal obesity alone, SSRIs other than paroxetine, warfarin, or an isolated single umbilical artery when the anatomy scan cardiac screening is normal.

    • A maternal or fetal indication supporting fetal cardiac assessment must be documented.

    Unsupported block type: denial_risk擬

    Prior Authorization

    Physician Review for Requests Not Meeting Criteria

    Requests that do not meet the applicable criteria, or that lack a criterion addressing the service, must be referred to a licensed physician for review. Only a physician of the same or similar specialty may issue an adverse determination after offering peer-to-peer discussion.

    • Automated systems and non-physician reviewers may approve in full or in part but may not issue an adverse determination.
    • The reviewing physician must satisfy applicable plan, licensure, specialty, and medical-director requirements.
    Moderate aortic stenosis or a thoracic aortic aneurysm of a given diameter
    Cardiotoxic cancer therapy
    AnthracyclinesIncluded when cardiac function monitoring is indicated
    HER2-targeted agentsIncluded when cardiac function monitoring is indicated
    Other qualifying exposuresImmune checkpoint inhibitors with suspected myocarditis, chest radiation including the heart, or other agents covered by labeling or cardio-oncology guidance
    Implanted cardiovascular physiologic monitor
    DefinitionImplanted device that records physiologic data
    Recorded dataThoracic impedance, heart-rate variability, activity, or hemodynamic pressures
    ExamplesDefibrillator or resynchronization devices with heart-failure diagnostic sensors and implanted hemodynamic sensors
    Red flag
    DefinitionFinding that changes the review pathway
    Urgent handlingMay require urgent handling or bypass stepwise or conservative-care requirements
    Safety roleIdentifies a safety concern that must be addressed before the service proceeds
    Low-risk acute chest pain
    Risk thresholdEstimated 30-day risk of death or major adverse cardiac events below 1 percent
    Clinical contextAcute chest pain
    Testing implicationFurther urgent cardiac testing may be deferred
    Comprehensive fetal echocardiography
    Standard timingComprehensive fetal cardiac study generally performed at 18 to 22 weeks' gestation
    Early high-risk timingEarly study at 12 to 14 weeks
    Follow-upEarly high-risk study is followed by a repeat second-trimester study